Trademark: ALECTOR 2253361
Word
ALECTOR
Device Descrption:
7 RECTANGLES,DIVIDED FORM GRAPH
ID
2253361
Trademark Type
Figurative
Status
Protected: Registered/protected
Application Date
02 December 2021
Registration Date
02 December 2021
Renewal Date
02 December 2031
Owner(s)
Service
Pizzeys Patent and Trade Mark Attorneys Pty Ltd
Goods and Services:
Class 5:
Pharmaceutical preparations for immunotherapy treatment; pharmaceutical preparations for the treatment of neurodegenerative and oncology diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for use in gene therapy; pharmaceutical preparations for the treatment of viral infections.
Pharmaceutical preparations for immunotherapy treatment; pharmaceutical preparations for the treatment of neurodegenerative and oncology diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for use in gene therapy; pharmaceutical preparations for the treatment of viral infections.
Class 44:
Providing medical information in the field of pharmaceuticals, immuno-oncology, immuno-neurology, neurodegenerative disorders, auto-immune disorders, and gene therapy; providing information in the medical field and in the field of pharmaceuticals, immuno-oncology, immuno-neurology, neurodegenerative disorders, auto-immune disorders, and gene therapy via a website; consulting in the field of pharmaceuticals, immuno-oncology, immuno-neurology, neurodegenerative disorders, auto-immune disorders, and gene therapy.
Providing medical information in the field of pharmaceuticals, immuno-oncology, immuno-neurology, neurodegenerative disorders, auto-immune disorders, and gene therapy; providing information in the medical field and in the field of pharmaceuticals, immuno-oncology, immuno-neurology, neurodegenerative disorders, auto-immune disorders, and gene therapy via a website; consulting in the field of pharmaceuticals, immuno-oncology, immuno-neurology, neurodegenerative disorders, auto-immune disorders, and gene therapy.